Orexin-A (Hypocretin-1): A Hypothalamic Neuropeptide in Wakefulness and Sleep-State Research

Research summary. Orexin-A (also known as hypocretin-1) is a 33-residue hypothalamic neuropeptide produced from the prepro-orexin precursor, which also gives rise to orexin-B (hypocretin-2). The orexin system is one of the dominant systems for stabilising wakefulness and inhibiting inappropriate transitions into rapid eye movement (REM) sleep; loss of orexin signalling is the established cause of human narcolepsy with cataplexy (narcolepsy type 1). Orexin-A is studied as a foundational tool molecule in sleep-wake biology and as a potential basis for orexin-replacement-style therapeutic strategies in narcolepsy.

Molecular profile

• Sequence: 33-residue peptide with two intramolecular disulfide bonds (Cys6–Cys12 and Cys7–Cys14)
• Class: Hypothalamic neuropeptide (orexin/hypocretin family)
• Receptor targets: Orexin receptor 1 (OX1R / HCRTR1) and orexin receptor 2 (OX2R / HCRTR2). Orexin-A binds both receptors with comparable affinity, while orexin-B is more selective for OX2R.
• Genomic origin: Encoded with orexin-B as a single prepro-orexin precursor (HCRT gene)

Discovery and biological context

The orexin/hypocretin system was independently discovered by two laboratories in 1998 — Sakurai and colleagues (who named the peptides "orexins" for their feeding-behaviour effects) and de Lecea and colleagues (who named them "hypocretins" for their hypothalamic localisation and incretin-like structure). Both nomenclatures persist in the literature. The system was rapidly linked to narcolepsy: orexin-deficient mice and orexin-receptor-2-deficient dogs both develop narcolepsy-like phenotypes, and human narcolepsy with cataplexy is associated with selective loss of hypothalamic orexin neurons.

Mechanism of action

Orexin-A is a non-selective agonist at OX1R and OX2R, both of which are Gαq-coupled GPCRs that drive intracellular calcium mobilisation. Orexin neurons project broadly throughout the CNS, with particularly dense projections to monoaminergic and cholinergic arousal nuclei (locus coeruleus, dorsal raphe, tuberomammillary nucleus, basal forebrain). Activation of these projections stabilises wakefulness, suppresses inappropriate REM-sleep transitions, and supports state stability. Loss of this signalling, as in narcolepsy type 1, produces the destabilised wake-sleep transitions and intrusion of REM-related phenomena (cataplexy, sleep paralysis, hypnagogic hallucinations) characteristic of the disorder.

Preclinical research highlights

Narcolepsy-cataplexy mouse models. A foundational body of research has used mice with selective ablation of orexin-producing neurons or with orexin-gene deletion. These models recapitulate human narcolepsy-type-1 phenotype, including cataplectic behavioural arrests and fragmented wake-sleep architecture. Central administration of Orexin-A in these models acutely increases wakefulness, suppresses sleep, and reduces cataplectic events — providing direct evidence that orexin-replacement strategies can rescue the core signalling deficit.

OX2R-selective signalling. Comparative studies have shown that the OX2R subtype carries the dominant signal for wakefulness stabilisation and cataplexy suppression, while OX1R contributes more to additional behavioural effects. This finding has driven recent therapeutic-development interest in OX2R-selective agonists.

Reward, feeding, and stress circuits. Orexin signalling has been implicated in feeding-behaviour regulation (the original "orexin" naming), reward circuitry (with implications for substance-use disorder research), and stress-system activation, providing a broader functional context beyond the narcolepsy framework.

Translational orexin-receptor pharmacology. Orexin-receptor antagonists (suvorexant, lemborexant, daridorexant) have been developed and FDA-approved for insomnia, validating the receptor system as drug-druggable. Orexin-receptor agonist development for narcolepsy is a more recent and active area, with TAK-861 / oveporexton and related candidates in late-stage clinical trials.

Translational considerations for orexin-replacement strategies

Direct administration of Orexin-A as a peptide therapeutic is constrained by the usual challenges of CNS-active peptide drugs: blood-brain-barrier penetration, oral bioavailability, and proteolytic stability. Most clinical development for orexin agonism in narcolepsy has therefore focused on small-molecule OX2R-selective agonists rather than the peptide itself. Orexin-A remains an essential research-grade tool molecule for mechanistic work in sleep-wake biology.

Current research status

Orexin-A is an investigational research peptide. It is not approved by the FDA as a therapeutic agent. Research interest is concentrated in narcolepsy mechanism studies, sleep-wake circuit pharmacology, reward and feeding-behaviour neuroscience, and as a comparator and tool molecule alongside the small-molecule OX2R agonists in clinical development.

For research-supplier contexts, Orexin-A is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

• Orexin-A (hypocretin-1) is a 33-residue hypothalamic neuropeptide that activates OX1R and OX2R to stabilise wakefulness and inhibit inappropriate REM-sleep transitions.
• Loss of orexin signalling is the established cause of human narcolepsy with cataplexy (narcolepsy type 1).
• Central administration of Orexin-A in orexin-deficient mouse models acutely rescues wakefulness and reduces cataplectic events.
• Orexin-receptor antagonists are FDA-approved for insomnia; orexin-receptor agonist development for narcolepsy is concentrated on small-molecule OX2R-selective agents in late-stage trials.
• Orexin-A itself is not an FDA-approved drug and remains primarily a research tool molecule.

References

1. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–585.
2. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. PNAS. 2004;101(13):4649–4654.

---

This article is provided for educational and research purposes only. Orexin-A is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.